Health
Interim Evaluation Of Respiratory Syncytial Virus Hospitalization Rates Among Infants And Young Children After Introduction Of Respiratory Syncytial Virus Prevention Products — United States, October
By Centers for Disease Control and Prevention | CDC (.gov)
Discussion
In 2024–25, the first U.S. RSV season with widespread availability of maternal RSV vaccine and nirsevimab, analyses of two population-based surveillance networks demonstrated significantly lower RSV-associated hospitalization rates among i ...Read more
